CLOUD technology enables the formulation of peptide, protein, and antibody therapeutics with stable, prolonged durations of action and predictable systemic exposures. CLOUD-based products incorporating aqueous-phase biologics or low molecular weight small molecules are capable of achieving days to weeks of sustained therapeutic activity following subcutaneous injection.

The CLOUD system—highly controllable and customizable—takes advantage of a novel noncovalent complexation process to reduce the solubility, manage the dissolution characteristics, and enhance the stability of the target active pharmaceutical ingredient (API). Once complexed, an API can be formulated in a low-viscosity aqueous or organic vehicle suitable for injection through a fine gauge needle.

CLOUD-based product candidates are in early preclinical development.